Press Releases Detail:
AVITAR launches ORALconfirmTM an oral fluid based confirmatory test for Substance Abuse Testing.
February 17, 2000
CANTON, MA, February 17, 2000 – Avitar, Inc. (NASD OTC: AVIT) announced today the launch of ORALconfirm™, an oral fluid based confirmatory test for drugs of abuse. Through the use of gas chromatography/mass spectrometry (GC/MS)—the widely recognized technology for confirmation testing in the industry—ORALconfirm validates a positive ORALscreen™ test for opiates, marijuana or cocaine.
"GC/MS is both legally-defensible and is the state-of-the-art technology for confirming substance abuse tests. Thus ORALconfirm represents an important step toward establishing oral fluid technology as the new industry standard," said Peter P. Phildius, chief executive officer and chairman of Avitar. "Furthermore, ORALconfirm combined with ORALscreen makes it possible for corporations and public safety organizations to completely eliminate the costly, burdensome and undignified process of urine collection and handling that has dominated substance abuse testing since its origin."
"ORALconfirm combines our patented oral fluid collection device with the most sensitive technology available to provide a legally-defensible, cutting-edge confirmatory testing service," said Doug Lewis, president of Avitar’s U.S. Drug Testing Laboratories. "Additionally, ORALconfirm provides an advantage over urine confirmatory tests for cases in which an ORALscreen test is administered immediately—such as post accident or probable cause testing—since it potentially detects the presence of cocaine and opiates as soon as they are ingested."
ORALconfirm will be marketed directly by Avitar to its ORALscreen customers.
Avitar, Inc. (NASDBB: AVIT.OB), headquartered in Canton, Massachusetts, develops, manufactures and markets innovative medical devices based on core technologies in oral fluid diagnostics and customized polyurethane applications. The company markets a unique portfolio of substance abuse testing products and services that includes the first point-of-contact rapid oral fluid screening device for drugs of abuse. Avitar also markets an oral fluid collection system for DNA testing, as well as a proprietary line of polyurethane-based high tech medical devices. For more information, see Avitar’s Web Site at avitarinc.com .
This release contains forward looking statements that are subject to risks and uncertainties, including the development of new applications that are detailed from time to time in the Company’s filings with the Securities and Exchange Commission.